The invention relates to the use of substance P antagonists and, inparticular, the use of non-peptidic NK1 receptor antagonists for the treatmentof cancer and, more specifically, human melanoma, neuroblastoma, glioma, humanHodgkin's lymphoma KM-H2, lymphoblastic leukaemia, human rhabdomyosarcoma,human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, humanEwing's sarcoma, human glioma and human osteosarcoma.